Physician profile
Patricia D Mulreany
NPI 1831105824
$1,515,272.38
in general payments reported to CMS, 2019-2025
19 companies · $635K in 2025
The $635K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122K · 2020: $116K · 2021: $140K · 2022: $164K · 2023: $178K · 2024: $161K · 2025: $635K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $635K · Royalty Or License: $338K · Food and Beverage: $522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $634,727.04 |
| Royalty Or License | $338,352.00 |
| Food and Beverage | $522.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pediatric Alliance LLC | $1,513,928.04 | 2019-2025 | |
| Corium, LLC | $261.47 | 2022-2024 | Azstarys |
| Kaleo, INC. | $175.37 | 2019-2024 | Auvi-Q |
| Pfizer INC. | $134.93 | 2019-2024 | |
| Cranial Technologies, INC | $134.42 | 2019-2023 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $114.53 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $106.89 | 2019-2024 | Jornay Pm |
| Alk-Abello, INC | $62.70 | 2024-2025 | Ragwitek, Odactra, Grastek |
| Merck Sharp & Dohme LLC | $60.12 | 2022-2023 | Vaxneuvance, M-M-R II, Vaxelis |
| Tris Pharma INC | $53.48 | 2021-2022 | |
| Seqirus USA INC | $47.55 | 2021-2024 | Flucelvax |
| Phadia US INC. | $32.24 | 2021-2024 | Immunocap |
| Shire North American Group INC | $30.82 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $26.52 | 2020 | |
| Adlon Therapeutics L.P. | $26.33 | 2020-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $25.00 | 2019 | |
| Supernus Pharmaceuticals, INC. | $19.53 | 2021 | |
| Kyowa Kirin, INC. | $17.50 | 2023 | Crysvita |
| Collegium Pharmaceutical, INC. | $14.94 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,572,072.57 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Mulreany listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.